The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma

Article English OPEN
Hernández-García, Susana; San-Segundo, Laura; González-Méndez, Lorena; Corchete, Luis A; Misiewicz-Krzeminska, Irena; Martín-Sánchez, Montserrat; López-Iglesias, Ana-Alicia; Algarín, Esperanza Macarena; Mogollón, Pedro; Díaz-Tejedor, Andrea; Paíno, Teresa; Tunquist, Brian; Mateos, María-Victoria; Gutiérrez, Norma C; Díaz-Rodriguez, Elena; Garayoa, Mercedes; Ocio, Enrique M;
(2017)
  • Publisher: Ferrara Storti Foundation
  • Journal: volume 102,issue 12,pages2,113-2,124issn: 0390-6078, eissn: 1592-8721
  • Related identifiers: doi: 10.3324/haematol.2017.168666, pmc: PMC5709111
  • Subject: Plasma Cell Disorders | Dexamethasone | :MEDICINE [Research Subject Categories] | Multiple myeloma | Kinesin spindle protein inhibitor | BAK activation | Filanesib | Article | Pomalidomide | Monopolar spindles

[EN]Kinesin spindle protein inhibition is known to be an effective therapeutic approach in several malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in heavily pre-treated multiple myeloma patients. The aim of the work herein wa... View more
Share - Bookmark